Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)
Clinical trial NCT03222973 · TERMINATED
Trial details
- NCT number
- NCT03222973
- Sponsor
- Biogen
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-15
- Primary completion
- 2021-02-12
- Enrollment
- 263
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.